They concluded that the presence of this mutation in RCCs shouldn't be thought of as a risk factor for recurrence, but rather the likelihood that the lesion is a PCP.13It has therefore been suggested to conduct confirmatory DNA sequencing following immunohistochemical analysis for BRAF p.V600E to fully differentiate RCCs and PCPs.13, 22, 26, 27. Here, BRAF is linked to pneumocystosis.